LCB 97
Alternative Names: LCB-97; ONO-7429Latest Information Update: 14 Aug 2026
At a glance
- Originator LegoChem Biosciences
- Developer LigaChem Biosciences; Ono Pharmaceutical
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 Jul 2026 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Japan (IV) (jRCT2041260054) (Ono pharma pipeline, July 2026)
- 10 Oct 2024 LCB 97 licensed to Ono Pharmaceutical in world
- 14 Apr 2023 Early research in Solid tumours in South Korea (Parenteral) prior to June 2023 (LegoChem Biosciences pipeline, June 2023)